.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Radiopharmaceutical Therapy Targeting PSMA for Prostate Cancer

A panel of experts along with a patient and caregiver discuss the emergence of PSMA-targeting therapy for patients with metastatic castration resistant prostate cancer (mCRPC).

EP. 1: Overview of Metastatic Castration Resistant Prostate Cancer (mCRPC)

June 1st 2022

An overview of metastatic castration-resistant prostate cancer (mCRPC) and the role of PSMA in mCRPC.

Latest News

FDA Grants Orphan Drug Designation to Novel CAR-T Cell Therapy to Treat Waldenstrom Macroglobulinemia, a Rare Type of Cancer

New Resource ‘Empowers’ Patients With Breast Cancer That Has Spread to the Brain With Much Needed Information

Cancer Boosted My Empathy, But Anger Is Starting to Rear Its Head

FDA Approves Breyanzi for Previously Treated Large B-Cell Lymphoma

View More Latest News